{"contentid": 488625, "importid": NaN, "name": "Phase III success for Keytruda combo in breast cancer", "introduction": "Merck & Co's checkpoint blocker and commercial super-blockbuster Keytruda (pembrolizumab) has scored another Phase III success, in triple-negative breast cancer (TNBC).", "content": "<p><span style=\"font-weight: 400;\">Merck &amp; Co&rsquo;s (NYSE: MRK) checkpoint blocker and commercial super-blockbuster Keytruda (pembrolizumab) has scored another Phase III success, in triple-negative breast cancer (TNBC).</span></p>\n<p><span style=\"font-weight: 400;\">Results from the KEYNOTE-522 trial show the benefits of combining the immunotherapy with chemotherapy as a pre-operative treatment and then continuing as a single agent after surgery.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The study met its dual primary endpoint of event-free survival (EFS) for the treatment of patients with high-risk early-stage TNBC, according to an interim analysis conducted by data monitors.</span></p>\n<p><span style=\"font-weight: 400;\">It was already known the trial had met its other dual primary endpoint of pathological complete response (pCR).&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies, and no new safety signals were identified.</span></p>\n<h2><strong>Bouncing back from FDA rejection</strong></h2>\n<p><span style=\"font-weight: 400;\">The results are significant, given that the company received a Complete Response Letter (CRL) from the US regulator for a submission in this indication in March 2021.</span></p>\n<p><span style=\"font-weight: 400;\">The US FDA&rsquo;s advisory panel voted unanimously that a regulatory decision should be deferred until further data were available from KEYNOTE-522.</span></p>\n<p><span style=\"font-weight: 400;\">Chief medical officer Roy Baynes said: &ldquo;Keytruda is the first immunotherapy to show positive results for event-free survival in patients with high-risk early-stage TNBC, a particularly aggressive form of breast cancer.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added that after seeing the data mature over four years, &ldquo;to include a statistically-significant improvement in event-free survival,&rdquo; Merck would work with regulators &ldquo;to bring this new option to patients as quickly as possible.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">The Keytruda clinical development program for TNBC encompasses several internal studies and external collaborative trials, including the ongoing studies KEYNOTE-242 and KEYNOTE-355.</span></p>\n<p><span style=\"font-weight: 400;\">Merck also has an expansive clinical development program investigating the therapy in earlier lines of therapy including in neoadjuvant, adjuvant and locally advanced settings, with approximately 20 registrational studies in progress.</span></p>", "date": "2021-05-13 14:56:00", "meta_title": NaN, "meta_keywords": "Keytruda, TNBC, breast, cancer, Merck, Phase, success, KEYNOTE-, studies, trial, data, results, event-free, survival, patients, pembrolizumab, checkpoint", "meta_description": "Merck & Co's checkpoint blocker and commercial super-blockbuster Keytruda (pembrolizumab) has scored another Phase III success, in triple-negative breast cancer", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-13 14:31:43", "updated": "2021-05-13 14:56:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/phase-iii-success-for-keytruda-combo-in-breast-cancer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "keytruda_big.png", "image2id": "keytruda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "Merck & Co", "drug_tag": "Keytruda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-13 14:56:00"}